

Clinical trials of canakinumab

TrialResults-center www.trialresultscenter.org

1 post myocardial infarction

Trial	Treatments	Patients	Trials design and methods
canakinumab vs placebo			
CANTOS , 2017 [NCT01327846] n=10066 follow-up: 36 months	Quarterly Subcutaneous Canakinumab 50mg, 150mg, 300mg for 36 months versus placebo	Stable Post-myocardial Infarction Patients With Elevated hsCRP	double-blind

More details and results :

- anti inflammatory drugs for post myocardial infarction in all type of patients at <http://www.trialresultscenter.org/go-Q684>

References

CANTOS, 2017:

Ridker PM, Thuren T, Zalewski A, Libby P Interleukin-1? inhibition and the prevention of recurrent cardiovascular events: rationale and design of the Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS). Am Heart J 2011;162:597-605 [21982649]

2 post acute coronary syndromes

Trial	Treatments	Patients	Trials design and methods
canakinumab vs placebo			
CANTOS , 2017 [NCT01327846] n=10066 follow-up: 36 months	Quarterly Subcutaneous Canakinumab 50mg, 150mg, 300mg for 36 months versus placebo	Stable Post-myocardial Infarction Patients With Elevated hsCRP	double-blind

More details and results :

- anti inflammatory drugs for post acute coronary syndromes in all type of patients at <http://www.trialresultscenter.org/go-Q683>

References

CANTOS, 2017:

Ridker PM, Thuren T, Zalewski A, Libby P Interleukin-1? inhibition and the prevention of recurrent cardiovascular events: rationale and design of the Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS). *Am Heart J* 2011;162:597-605 [[21982649](#)]